| Literature DB >> 35423146 |
Lei Xu1, Xiaofei Li1, Yumeng Zhang1, Meng Ding1, Baoshan Sun1, Guangyue Su1, Yuqing Zhao1,2.
Abstract
The Shenque acupoint is located in the umbilicus of the human body. In the human body meridians, the Shenque acupoint can regulate body functions. The Shenque acupoint was one of the important acupuncture acupoints for the treatment of insomnia. However, the effect of linalool applied at the Shenque acupoint to improve sleep was unknown. This study explored the hypnotic and sedative effects of the main component of lavender, linalool, on the Shenque acupoint of mice and rats. The effects on the sleep latency and sleep duration were studied with the supra-threshold dose of pentobarbital sodium, and the effects on the sleep rate were studied with the sub-threshold dose of pentobarbital sodium. In order to further study the feasibility and superiority of linalool administered at the Shenque acupoint, a pharmacokinetic study was carried out. The pharmacodynamic results showed that the mice and rats treated with linalool at Shenque had the highest sleep rate, the shortest sleep latency, and the longest sleep duration compared with other groups. The T max and t 1/2 of the LS were longer than those of the LO, and had the characteristics of sustained release. The relative bioavailability of LS was 323.0 ± 31.66%. This showed that the combination of linalool and the Shenque acupoint had greater medicinal effects. This development will provide a new direction for improving sleep. This journal is © The Royal Society of Chemistry.Entities:
Year: 2021 PMID: 35423146 PMCID: PMC8694721 DOI: 10.1039/d0ra09751a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 3.361
Fig. 1The chemical structure of linalool.
Fig. 2GC chromatograms of linalool (A) and lavender oil (B) (linalool RT = 12.34 min).
Fig. 3Determination of the sleep rates of rats and mice. (A) The sleep rate of mice. (B) The sleep rate of rats (LS: the linalool Shenque acupoint group; LaS: the lavender Shenque acupoint group; LaO: the lavender oral group; LaI: the lavender inhalation group; diazepam: the positive control group; ***P < 0.001, **P < 0.01, *P < 0.05).
Sub-threshold dose sleep latency and sleep duration tests of pentobarbital sodium in mice and rats in the different groupsa
| Groups | Samples | Mice | Rats | ||||
|---|---|---|---|---|---|---|---|
| Dose (mg kg−1) | Sleep latency (min) | Sleep duration (min) | Dose (mg kg−1) | Sleep latency (min) | Sleep duration (min) | ||
| Control | 10 | 11.90 ± 3.11 | 38.20 ± 15.67 | 8.50 ± 2.10 | 20.00 ± 5.30 | ||
| LS | 10 | 400 | 5.88 ± 1.72*** | 81.90 ± 19.70*** | 300 | 5.10 ± 0.44** | 64.40 ± 11.29*** |
| LaS | 10 | 400 | 6.20 ± 3.02* | 69.60 ± 11.90** | 300 | 5.56 ± 1.20* | 62.34 ± 12.20*** |
| LaO | 10 | 400 | 8.30 ± 3.52* | 40.30 ± 8.32 | 300 | 7.42 ± 1.60 | 38.65 ± 8.45 |
| LaI | 10 | 0.03 | 6.40 ± 3.10** | 58.75 ± 10.60** | 0.03 | 6.20 ± 0.70* | 50.20 ± 10.10** |
| Diazepam | 10 | 5 | 6.20 ± 1.40*** | 65.47 ± 12.10** | 3.5 | 5.25 ± 0.48** | 63.50 ± 10.50*** |
Compared with the control group, ***P < 0.001, **P < 0.01, *P < 0.05.
Fig. 4Specificity investigation. (A) Blank plasma; (B) blank plasma + linalool + internal standard; (C) plasma after oral administration of linalool for 10 min added with the internal standard. (1) Linalool; (2) nifedipine (internal standard).
Results from the analytical methods validation
| Parameter | Result |
|---|---|
| Linearity | 0.1–3 μg mL−1 |
| Correlation coefficient |
|
| Limit of quantification | 0.1 μg mL−1 |
| Limit of detection | 0.03 μg mL−1 |
| Stability | |
| Short term | 87.56–100.2% |
| Freeze and thaw cycles | 93.45–103.7% |
| Autosampler | 95.92–100.7% |
| Precision (CV%) | |
| Intraday | 7.1 |
| Interday | 9.0 |
| Accuracy (RE%) | |
| Intraday | 4.4 |
| Interday | 6.5 |
| Recovery (%) | 87 |
Fig. 5Plasma concentration–time curves for the LS and the LO (n = 6) (LS: the linalool Shenque acupoint group; LO: linalool oral group).
Pharmacokinetic parameters after administration in rats (n = 6)a
| Parameter | LO | LS |
|---|---|---|
|
| 164.7 ± 26.39 | 214.9 ± 151.4 |
|
| 1.92 ± 0.12 | 2.29 ± 0.15*** |
|
| 40.0 ± 0.35 | 60.0 ± 0.42 |
| AUC0– | 116.2 ± 6.45 | 373.2 ± 15.96*** |
| AUC0–∞ (μg mL−1 min−1) | 147.9 ± 10.51 | 452.9 ± 85.81*** |
| MRT0– | 63.01 ± 7.19 | 155.5 ± 3.33*** |
| MRT0–∞ (min) | 154.6 ± 18.91 | 282.9 ± 126.9*** |
| Fr (%) | — | 323.0 ± 31.66 |
***P < 0.001, *P < 0.05.